As of 4:00pm ET
| -0.06 / -1.91%|
The 3 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 5.50, with a high estimate of 9.25 and a low estimate of 5.00. The median estimate represents a +78.57% increase from the last price of 3.08.
The current consensus among 5 polled investment analysts is to Hold stock in ZIOPHARM Oncology Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.